Skip to main content

Ovarian Cancer Clinical Trials

Review the ovarian cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 101-125 of 277

Dostarlimab and LB-100 for the Treatment of Patients with Recurrent Ovarian Clear Cell Carcinoma, Peritoneal, or Fallopian Tube Cancer
Status: Active
Location: 2 locations
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Status: Active
Location: 2 locations
A Beta-only IL-2 ImmunoTherapY Study
Status: Active
Location: 2 locations
DT2216 with Paclitaxel for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Status: Active
Location: 2 locations
Study of STP938 in Advanced Solid Tumours
Status: Active
Location: 2 locations
Cytokine-Induced Memory-Like Natural Killer Cell Therapy for the Treatment of Recurrent Ovarian Cancer
Status: Active
Location: 2 locations
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Status: Active
Location: 2 locations
Cirtuvivint and Olaparib for the Treatment of Patients with BRCA/HRD Platinum Resistant Ovarian Cancer
Status: Active
Location: 2 locations
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Status: Active
Location: 2 locations
Niraparib for Maintenance Treatment in Women of African Ancestry with Stage III-IV Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer after Front-line Treatment
Status: Active
Location: 2 locations
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Status: Active
Location: 4 locations
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Nab-Sirolimus and Fulvestrant for the Treatment of Recurrent Low Grade Serous Ovarian Cancer
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
PLX038 for the Treatment of Patients with Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Carboplatin, Paclitaxel, and Pembrolizumab Before Surgery Followed by Olaparib and Pembrolizumab with or without Bevacizumab for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
APL-2 and Pembrolizumab versus APL-2, Pembrolizumab and Bevacizumab versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Biomarkers for Predicting Response to SAR444881 in Combination with Cemiplimab in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, or Ovarian Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemotherapy with or without HCW9218 before Surgery for the Treatment of Stage III-IV High Grade Serous Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Autophagy Maintenance Therapy (Hydroxychloroquine and Nelfinavir) plus Bevacizumab for the Treatment of Recurrent High-Grade Serous Ovarian, Fallopian Tube, and Primary Peritoneal Cancer, AUTOMAIN Trial
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Status: Active
Location: 3 locations
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland